Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 1336 AL 1350

Pure Autonomic Failure

Thaisetthawatkul P.

Curr Neurol Neurosci Rep. 2016 Aug;16(8):74. doi: 10.1007/s11910-016-0673-2.

Patients' experiences of deep brain stimulation for Parkinson's disease: a qualitative systematic review and synthesis

Mathers J, Rick C, Jenkinson C, Garside R, Pall H, Mitchell R, Bayliss S, Jones LL.

BMJ Open. 2016 Jun 23;6(6):e011525. doi: 10.1136/bmjopen-2016-011525.

TSPO imaging in parkinsonian disorders

Gerhard A.

Clin Transl Imaging. 2016;4:183-190. doi: 10.1007/s40336-016-0171-1. Epub 2016 Apr 11.

Autonomic Dysfunction: How to Identify and When to Treat?

Saladini F, Di Marco A, Palatini P.

High Blood Press Cardiovasc Prev. 2016 Sep;23(3):237-43. doi: 10.1007/s40292-016-0162-3. Epub 2016 Jun 24.

Effects of levodopa therapy on global left ventricular systolic function in patients with Parkinson disease

Günaydın ZY, Bektaş O, Karagöz A, Özer FF.

Wien Klin Wochenschr. 2016 Jul;128(13-14):528-33. doi: 10.1007/s00508-016-1026-5. Epub 2016 Jun 24.

Atomoxetine restores the response inhibition network in Parkinson's disease

Rae CL, Nombela C, Rodríguez PV, Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB.

Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24.

Current drug treatments targeting dopamine D3 receptor

Leggio GM, Bucolo C, Platania CB, Salomone S, Drago F.

Pharmacol Ther. 2016 Sep;165:164-77. doi: 10.1016/j.pharmthera.2016.06.007. Epub 2016 Jun 22.

Myeloperoxidase: Bridging the gap in neurodegeneration

Ray RS, Katyal A.

Neurosci Biobehav Rev. 2016 Sep;68:611-620. doi: 10.1016/j.neubiorev.2016.06.031. Epub 2016 Jun 22.

Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease

Perez-Lloret S, Rascol O.

CNS Drugs. 2016 Aug;30(8):703-17. doi: 10.1007/s40263-016-0360-5.

Cytoplasmic aggregates of dynactin in iPSC-derived tyrosine hydroxylase-positive neurons from a patient with Perry syndrome

Mishima T, Ishikawa T, Imamura K, Kondo T, Koshiba Y, Takahashi R, Takahashi J, Watanabe A, Fujii N, Tsuboi Y, Inoue H.

Parkinsonism Relat Disord. 2016 Sep;30:67-72. doi: 10.1016/j.parkreldis.2016.06.007. Epub 2016 Jun 15.

Severe, Symptomatic, Self-limited Unilateral DBS Lead Edema Following Bilateral Subthalamic Nucleus Implantation: Case Report and Review of the Literature

Gerard CS, Metman LV, Pal G, Karl J, Sani S.

Neurologist. 2016 Jul;21(4):58-60. doi: 10.1097/NRL.0000000000000082.

Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca(2+)/cAMP intracellular signalling interaction

Bergantin LB, Caricati-Neto A.

Eur J Pharmacol. 2016 Oct 5;788:255-260. doi: 10.1016/j.ejphar.2016.06.034. Epub 2016 Jun 24.

The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms

Lan AP, Chen J, Chai ZF, Hu Y.

Biometals. 2016 Aug;29(4):665-78. doi: 10.1007/s10534-016-9942-4. Epub 2016 Jun 27.

Current Topics in Deep Brain Stimulation for Parkinson Disease

Umemura A, Oyama G, Shimo Y, Nakajima M, Nakajima A, Jo T, Sekimoto S, Ito M, Mitsuhashi T, Hattori N, Arai H.

Neurol Med Chir (Tokyo). 2016 Oct 15;56(10):613-625. doi: 10.2176/nmc.ra.2016-0021. Epub 2016 Jun 24.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias